Organ motion in pediatric high‐risk neuroblastoma patients using four‐dimensional computed tomography
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Applied Clinical Medical Physics"
DOI: 10.1002/acm2.12012
Abstract: Abstract Purpose/objective(s) High‐risk neuroblastoma (HR‐NBL) requires multimodality treatment, including external beam radiation of the primary tumor site following resection. Radiotherapy planning must take into account motion of the target and adjacent normal anatomy, both of… read more here.
Keywords: organ motion; motion; high risk; risk neuroblastoma ... See more keywords
Efficacy of post‐induction therapy for high‐risk neuroblastoma patients with end‐induction residual disease
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34263
Abstract: High‐risk neuroblastoma patients with end‐induction residual disease commonly receive post‐induction therapy in an effort to increase survival by improving the response before autologous stem cell transplantation (ASCT). The authors conducted a multicenter, retrospective study to… read more here.
Keywords: end induction; patients end; risk neuroblastoma; high risk ... See more keywords
Sarcopenia and preserved bone mineral density in paediatric survivors of high‐risk neuroblastoma with growth failure
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Cachexia, Sarcopenia and Muscle"
DOI: 10.1002/jcsm.12734
Abstract: Survival from paediatric high‐risk neuroblastoma (HR‐NBL) has increased, but cis‐retinoic acid (cis‐RA), the cornerstone of HR‐NBL therapy, can cause osteoporosis and premature physeal closure and is a potential threat to skeletal structure in HR‐NBL survivors.… read more here.
Keywords: preserved bone; sarcopenia preserved; high risk; density ... See more keywords
Phase I/II clinical trial of high-dose [131I] meta-iodobenzylguanidine therapy for high-risk neuroblastoma preceding single myeloablative chemotherapy and haematopoietic stem cell transplantation
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-021-05630-7
Abstract: Paediatric high-risk neuroblastoma has poor prognosis despite modern multimodality therapy. This phase I/II study aimed to determine the safety, dose-limiting toxicity (DLT), and efficacy of high-dose 131I-meta-iodobenzylguanidine (131I-mIBG) therapy combined with single high-dose chemotherapy (HDC)… read more here.
Keywords: high dose; high risk; stem cell; risk neuroblastoma ... See more keywords
Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer cell"
DOI: 10.1016/j.ccell.2016.12.002
Abstract: Given the paucity of druggable mutations in high-risk neuroblastoma (NB), we undertook chromatin-focused small interfering RNA and chemical screens to uncover epigenetic regulators critical for the differentiation block in high-risk NB. High-content Opera imaging identified… read more here.
Keywords: risk; chemical screens; high risk; setd8 inhibition ... See more keywords
Interpretable models for high-risk neuroblastoma stratification with multi-cohort copy number profiles
Sign Up to like & getrecommendations! Published in 2021 at "Informatics in Medicine Unlocked"
DOI: 10.1016/j.imu.2021.100701
Abstract: Abstract Although high-risk neuroblastoma (HR-NB) is clinically heterogeneous, it is treated in a similar fashion without additional risk stratification. Based on the 4 copy-number profiles with 556 HR-NB subjects and 14 potential risk factors of… read more here.
Keywords: stratification; copy number; risk; number profiles ... See more keywords
Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma
Sign Up to like & getrecommendations! Published in 2017 at "Pediatric Hematology and Oncology"
DOI: 10.1080/08880018.2017.1373314
Abstract: ABSTRACT The metronomic therapy concept uses low doses of continuously applied chemotherapeutic, anti-angiogenetic, and immunomodulating drugs. Twenty patients with recurrent and 3 with refractory high-risk neuroblastoma were treated by the metronomic concept using celecoxib, cyclophosphamide,… read more here.
Keywords: metronomic therapy; high risk; treatment; risk neuroblastoma ... See more keywords
The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2018.1549221
Abstract: ABSTRACT Introduction: Dinutuximab, an anti-GD2 antibody, specifically targets the high-expression of GD2 on neuroblastoma cells, and its incorporation into maintenance high-risk neuroblastoma therapy has increased event-free survival for this devastating disease. Efficacy of dinutuximab during… read more here.
Keywords: high risk; treatment; safety; dinutuximab ... See more keywords
Identification of Mitochondrial DNA Variants Associated With Risk of Neuroblastoma.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the National Cancer Institute"
DOI: 10.1093/jnci/djac012
Abstract: Neuroblastoma is a childhood cancer that originates in the developing sympathetic nervous system. We previously reported a crucial role of mitochondrial DNA (mtDNA) haplogroups in the pathology of neuroblastoma. To pinpoint mtDNA variants associated with… read more here.
Keywords: risk; mitochondrial dna; neuroblastoma; variants associated ... See more keywords
Dinutuximab beta in the treatment of high-risk neuroblastoma
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000028716
Abstract: Abstract Despite therapeutic advances, high-risk neuroblastoma is still associated with a poor long-term prognosis. Immunotherapy with the anti-GD2 antibody dinutuximab beta has recently been added to the standard of care for patients with high-risk neuroblastoma… read more here.
Keywords: beta; risk neuroblastoma; dinutuximab beta; high risk ... See more keywords
Late Effects in Pediatric High-risk Neuroblastoma Survivors After Intensive Induction Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Triple Autologous Stem Cell Transplants
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000000848
Abstract: Multimodal treatment in high-risk neuroblastoma has modestly improved survival; limited data exist on the late effects from these regimens. We report the sequelae of treatment incorporating 3 consecutive cycles of high-dose therapy and autologous stem… read more here.
Keywords: chemotherapy; high risk; late effects; risk neuroblastoma ... See more keywords